Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011075838 - METHOD OF TREATING OR PREVENTING HEARING LOSS

Publication Number WO/2011/075838
Publication Date 30.06.2011
International Application No. PCT/CA2010/002037
International Filing Date 21.12.2010
IPC
A61K 47/42 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
A61N 1/32 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
1Electrotherapy; Circuits therefor
18Applying electric currents by contact electrodes
32alternating or intermittent currents
A61P 27/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27Drugs for disorders of the senses
16Otologicals
A61K 48/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/861 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
861Adenoviral vectors
C12N 15/87 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
CPC
A61K 38/1761
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
1703from vertebrates
1709from mammals
1761Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
A61K 47/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
A61K 9/0046
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0046Ear
C12N 2750/14143
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2750ssDNA Viruses
00011ssDNA Viruses
14011Parvoviridae
14111Dependovirus, e.g. adenoassociated viruses
14141Use of virus, viral particle or viral elements as a vector
14143viral genome or elements thereof as genetic vector
Applicants
  • AUDIGEN INC. [CA]/[CA] (AllExceptUS)
  • BANCE, Manohar [CA]/[CA] (UsOnly)
  • ROBERTSON, George [CA]/[CA] (UsOnly)
  • WANG, Jian [CA]/[CA] (UsOnly)
Inventors
  • BANCE, Manohar
  • ROBERTSON, George
  • WANG, Jian
Agents
  • FASKEN MARTINEAU DUMOULIN LLP
Priority Data
61/288,52621.12.2009US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHOD OF TREATING OR PREVENTING HEARING LOSS
(FR) PROCÉDÉ POUR TRAITEMENT OU PRÉVENTION DE PERTE D'AUDITION
Abstract
(EN)
Disclosed herein is a method of delivering a mutated tyrosine adeno-associated viral vector or a pharmaceutically active agent to an inner ear. The method comprises contacting the round window membrane with the vector or the pharmaceutically active agent, in which the permeability of the round window membrane having been enhanced to allow transport of the vector or the pharmaceutically active agent across it so as to deliver the vector or the pharmaceutically active agent to the inner ear. Also disclosed are methods to prevent or treat hearing loss and impaired balance in human subjects using the delivery method.
(FR)
La présente invention concerne un procédé permettant d'administrer dans une oreille interne un vecteur viral muté, adéno-associé à la tyrosine, ou un agent pharmaceutiquement actif. Ce procédé consiste à faire toucher le tympan secondaire par le vecteur ou l'agent pharmaceutiquement actif, la perméabilité du tympan secondaire ayant été accrue pour en permettre la traversée par le vecteur ou par l'agent pharmaceutiquement actif, de façon à administrer dans l'oreille interne le vecteur ou l'agent pharmaceutiquement actif. L'invention concerne également des procédés qui utilisent ce mode d'administration, et qui sont destinés à la prévention ou au traitement de la perte d'audition ou des troubles de l'équilibre affectant des humains.
Latest bibliographic data on file with the International Bureau